Viridian Therapeutics, Inc. VRDN Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

Immunovant, Inc.IMVT

$126K-60.5%

PVL

Palvella TherapeuticsPVLA

$38.5K—

Nektar TherapeuticsNKTR

——

Other financials

Income statement

See full

Revenue$141.0K+95.8%

Operating income-$116.2M-23.8%

Net income-$104.9M-20.7%

EPS (diluted)-$1.15-5.5%

Balance sheet

See full

Cash & equivalents$176.3M+51.7%

Total debt$36.8M+59.4%

Total equity$636.0M+5.2%

Total assets$789.0M+19.4%

Cash flow

See full

Operating cash flow-$119.7M-29.1%

CapEx$23.0K-73.3%

Free cash flow-$119.7M-29.0%

Valuation

See full

Market cap$1.91B+82.0%

Profitability

See full

Gross margin36.3%—

Operating margin-543.9%-271pp

Net margin-508.5%-254pp

FCF margin-428.4%-214pp

Returns & leverage

See full

Return on equity-58.1%+7.9pp

Debt / equity0.1×0.0×

Current ratio15.1×-4.3×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viridian Therapeutics, Inc.'s payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Viridian Therapeutics, Inc.'s payments of stock issuance costs?: Viridian Therapeutics, Inc. (VRDN) reported payments of stock issuance costs of $0 in Q1 2026.
How has Viridian Therapeutics, Inc.'s payments of stock issuance costs changed year-over-year?: Viridian Therapeutics, Inc.'s payments of stock issuance costs decreased by 100.0% year-over-year, from $207K to $0.